Cytovia has been built through multiple collaborations with academic researchers, leading medical centers, and strategic partners. We aim to accelerate the transformation of cancer therapy and develop first-in-class products in areas of major unmet medical need.


As Cytovia matures its gene-edited iPSC NK / CAR-NK and Multispecific NK Engager platforms, we are open to research partnerships and co-development with academic institutions and industry partners to broaden the use of NK Cell Therapies. If interested, please email Armin Rath, PhD (VP, Business Development and Alliance Management) at